FLB.F Fluidigm Corporation

Healthcare Biotechnology Frankfurt Exchange
0.6000 EUR
Close of Nov 11, 2026
0.5300 1.42
Market cap
EUR 237M
P/E
-
P/B
0.49x
ROE
27.3%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is FLB.F undervalued?

Graham number

The Graham number of Fluidigm Corporation cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Fluidigm Corporation fundamental analysis

No fundamental analysis for Fluidigm Corporation yet.

Fluidigm Corporation stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Fluidigm Corporation

Standard BioTools Inc., together with its subsidiaries, develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics in the Americas, Europe, the Middle East, Africa, and the Asia pacific. The company operates through Proteomics and Genomics segments. Its proteomics and genomics include instruments, consumables, and assays for clinical and diagnostic uses. The company also provides So…

Full company profile